<DOC>
	<DOCNO>NCT02580305</DOCNO>
	<brief_summary>This phase 2a , proof-of-concept , 26-week , double-blind , multicenter , randomize , parallel group , placebo-controlled study compare efficacy safety treatment SUVN-502 placebo treatment subject moderate Alzheimer 's disease receive stable dos donepezil HCl memantine HCl .</brief_summary>
	<brief_title>SUVN-502 With Donepezil Memantine Treatment Moderate Alzheimer 's Disease- Phase 2a Study</brief_title>
	<detailed_description>This phase 2a , proof-of-concept , 26-week , double-blind , multicenter , randomize , parallel group , placebo-controlled study compare efficacy safety treatment SUVN-502 placebo treatment subject moderate Alzheimer 's disease receiving donepezil HCl ( 10 mg qd ) either memantine HCl ( 10 mg twice daily [ bid ] ) Namenda XR® ( 28 mg qd ) combination therapy , Namzaric™ The primary objective study evaluate efficacy serotonin receptor subtype 6 ( 5-HT6 ) antagonist , SUVN-502 , compare placebo , adjunct treatment subject moderate Alzheimer 's disease ( Mini-Mental State Examination [ MMSE ] score 12 20 ) currently treat acetylcholinesterase inhibitor , donepezil hydrochloride ( HCl ) , N-methyl-D-aspartic acid ( NMDA ) antagonist , memantine HCl . Efficacy assess 11-item Alzheimer 's Disease Assessment Scale Cognitive Behavior ( ADAScog-11 ) 26 week treatment .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Has diagnosis probable Alzheimer 's disease base NINCDSADRDA criterion least 1 year prior screen visit . Has score 12 20 inclusive MMSE screen baseline visit . Has MRI CT scan perform within 12 month prior screen finding consistent diagnosis dementia due Alzheimer 's disease without clinically significant comorbid pathology . Must receive treatment stable dos donepezil HCl memantine HCl least 3 month prior screen visit Availability eligible reliable caregiver Must living community assist living facility . Must ambulatory ambulatory aid ( use cane walker ) . Is pregnant plan become pregnant study . Subject ( subject 's legally acceptable representative ) caregiver must sign Informed Consent participate study . Has diagnosis dementia due Alzheimer 's Disease Is take cholinesterase inhibitor donepezil HCl take dos donepezil HCl 10 mg Is take dos memantine HCl 10 mg bid Namenda XR® 28 mg qd . Has uncontrolled cardiac disease hypertension . Has clinically significant renal hepatic impairment . Has cancer malignant tumor , untreated thyroid disorder history seizure disorder Is treat likely require treatment study , medication prohibit study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>SUVN-502</keyword>
	<keyword>5-HT6</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Cognition</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Memantine</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>